Skip to content

Rheumatoid arthritis — synovial immunobiology

TL;DR — The RA synovium is an organized, heterogeneous tissue ecosystem rather than a uniform mass of inflammatory cells. T and B lymphocytes, plasma cells, macrophages, neutrophils, endothelial cells, fibroblast states, osteoclasts, and extracellular matrix interact through TNF, IL-6, chemokines, growth factors and cell contact (Jang 2022, PMID 35055087). TNF, IL-6 receptor, B-cell and T-cell-costimulation therapies validate several nodes clinically, but no single pathway explains all disease or all nonresponse. Single-cell and spatial work separates lining, sublining and lymphoid-rich states and identifies fibroblast/macrophage subsets associated with inflammation or damage, without yet proving that these states are stable causes or usable treatment selectors (Schonfeldova 2022, PMID 34559213). Bone erosion emerges from inflammatory RANKL–osteoclast signaling plus impaired repair (Komatsu 2022, PMID 35705856).

Normal synovium and pathological transformation

Normal synovium maintains a low-friction joint through a thin lining, resident macrophages and fibroblasts, vascular supply, and synovial fluid. RA converts this into hyperplastic, vascular, leukocyte-rich tissue capable of invading cartilage and supporting osteoclastogenesis.

Compartment/cell Homeostatic role RA-associated behavior
Lining macrophages Barrier and debris clearance Barrier disruption; inflammatory mediator production
Lining fibroblasts Lubrication and matrix maintenance Matrix degradation and invasion
Sublining fibroblasts Stromal support Chemokines, leukocyte retention, RANKL
Endothelium Controlled trafficking Angiogenesis and sustained recruitment
T cells Immune surveillance Costimulation, cytokines, B-cell/macrophage help
B/plasma cells Antibody responses Autoantibody and antigen-presentation programs
Neutrophils Acute defense Synovial-fluid enzymes, oxidants and NETs
Osteoclasts Bone remodeling Focal erosion at pannus–bone interface

Resident macrophage and fibroblast subsets can restrain inflammation in health; disease reflects loss of regulatory architecture as well as gain of inflammatory cells (Knab 2022, PMID 35547214; Kemble 2021, PMID 34539648).

Adaptive immunity

HLA class II risk and ACPA implicate antigen presentation and CD4 T-cell help. T-cell costimulation is clinically validated by abatacept, while B-cell contribution is validated by rituximab. B cells may act through autoantibody production, antigen presentation, cytokines and ectopic lymphoid organization; response to depletion is incomplete because not all synovia are B-cell rich (Jang 2022, PMID 35055087; Humby 2021, PMID 33485455).

Adaptive component Evidence Unresolved issue
ACPA/RF Precede arthritis; associate with phenotype Which antibodies are pathogenic versus markers
CD4 T cells HLA link and costimulation target Dominant antigen(s) and tissue residence
B cells Rituximab efficacy Why synovial B-cell-poor disease sometimes responds
Plasma cells Local antibody production Resistance to CD20 depletion
Ectopic lymphoid structures Present in a subset Stability and predictive utility

Innate immunity and cytokines

Macrophage-derived TNF and IL-6 are central amplifiers. TNF blockade suppresses signs, symptoms and structural progression in many patients; IL-6 receptor blockade can work as monotherapy and after TNF failure (Lipsky 2000, PMID 11096166; Gabay 2013, PMID 23515142). Therapeutic validation is strong evidence that a pathway matters, but response does not establish the initiating lesion.

Axis Principal effects Therapeutic status
TNF Endothelial activation, cytokine amplification, pain, osteoclast support Multiple effective inhibitors
IL-6/JAK/STAT Acute-phase response, lymphocyte and stromal signaling IL-6R antibodies and JAK inhibitors effective
IL-1 Cartilage/bone inflammatory effects Limited role of IL-1 blockade in routine RA
GM-CSF Myeloid survival/activation Investigational
Chemokines Cell recruitment and tissue organization Redundancy has limited translation
RANKL Osteoclast differentiation Mechanistically validated; anti-RANKL affects bone

Fibroblast states and tissue memory

RA synovial fibroblasts remain activated ex vivo, invade cartilage in experimental systems, and occupy anatomically and functionally distinct niches (Pap 2000, PMID 11094449). Single-cell studies distinguish inflammatory sublining and destructive lining-associated programs, but nomenclature and sampling vary (Schonfeldova 2022, PMID 34559213; Cheng 2021, PMID 34349767).

Fibroblast “imprinting” could explain local persistence after systemic inflammation falls. Alternatives include continuous cytokine stimulation, altered matrix, metabolic constraints and recurrent immune recruitment. Longitudinal human tissue is needed to distinguish memory from repeated exposure.

Bone and cartilage damage

Inflammatory cytokines and fibroblast RANKL promote osteoclast differentiation; matrix metalloproteinases and other enzymes degrade cartilage. Bone formation is simultaneously suppressed, so erosion repair is limited even when inflammation is controlled (Komatsu 2022, PMID 35705856; Matsuda 2023, PMID 36982247).

Structural process Dominant cells/signals Clinical readout
Bone erosion Osteoclasts, RANKL, TNF Radiograph, CT, MRI erosion
Cartilage loss Fibroblasts, chondrocytes, proteases Joint-space narrowing
Osteitis Marrow inflammatory infiltrates MRI bone-marrow edema
Systemic bone loss Inflammation, glucocorticoids, inactivity BMD and fracture
Failed repair Impaired osteoblast function Persistent erosion despite remission

Tissue pathotypes and heterogeneity

Proposed pathotypes include lympho-myeloid, diffuse-myeloid and pauci-immune/fibroid patterns. They correlate imperfectly with molecular programs and treatment response. R4RA enrolled 164 anti-TNF inadequate responders and demonstrated multicenter biopsy-based randomization; low/absent B-cell signatures favored tocilizumab over rituximab in prespecified analyses, but assay and threshold replication are required (Humby 2021, PMID 33485455; Rivellese 2022, PMID 35589854).

Interpretation rule

Therapeutic response validates pathway relevance but does not prove that the targeted pathway initiated disease or is dominant in every joint.

Cell-state resolution and unresolved causality

Evidence layer Finding What remains unresolved
Multimodal single-cell atlas More than 314,000 cells from 79 donors resolved six cell-type abundance phenotypes, from lymphocyte-rich to lymphocyte-poor, with associations to cytokines, risk genes and response (Zhang 2023, PMID 37938773). Whether CTAP-guided drug selection outperforms ordinary treat-to-target sequencing.
Macrophage state Modern single-cell work separates inflammatory monocyte-derived populations from tissue-resident macrophages that form a protective lining barrier and participate in remission (Kurowska-Stolarska 2022, PMID 35672464). Whether expanding protective states is feasible without impairing host defense.
Myeloid pathotype Cross-pathotype deconvolution linked COL3A1-positive macrophages to remission biology (Hu 2024, PMID 38601143). Association with remission does not establish that this subset causes or maintains it.
T peripheral helper cells PD-1-high CXCR5-negative Tph cells were increased tenfold in early RA synovial follicular and diffuse regions and localized near germinal-center B cells (Murray-Brown 2022, PMID 36270740). Tph-directed intervention could also disrupt protective humoral immunity.
Spatial organization Three-dimensional spatial transcriptomics mapped cell-specific programs around organized leukocyte aggregates (Vickovic 2022, PMID 35149753). Small tissue fields and biopsy site selection may not represent the whole patient.
Molecular remission Longitudinal blood transcriptome, proteome and immunophenotype moved toward healthy profiles after therapy, but treatment-resistant signatures persisted (Tasaki 2018, PMID 30013029). Clinical remission and molecular normalization are overlapping, not identical, endpoints.

These datasets strengthen a network model: cytokine blockade succeeds because TNF or IL-6 is a high-connectivity node, not because every joint has the same upstream driver. The competing interpretation is that observed cell states are consequences of treatment, duration, or anatomic sampling. Longitudinal, multisite biopsies tied to randomized treatment interactions—not cross-sectional clustering alone—are required to distinguish mechanism from state marker.

Evidence map

This map adds directly adjacent evidence used to bound interpretation. Inclusion means the record informs this topic or a tightly linked decision; it does not imply that every study supports every conclusion on the page.

Adjacent evidence Relevance to this page
Bhamidipati K, et al. Precision medicine in rheumatoid arthritis. Nat Rev Rheumatol. 2022. (PMID 35248489) Adjacent evidence from biomarkers-and-tissue-precision.md, genetics-environment-and-mucosal-origins.md, preclinical-autoimmunity-and-prevention.md
Atzeni F, et al. Biomarkers in rheumatoid arthritis. Mediators Inflamm. 2017. (PMID 28825772) Adjacent evidence from biomarkers-and-tissue-precision.md, genetics-environment-and-mucosal-origins.md, preclinical-autoimmunity-and-prevention.md
van Heemst J, et al. HLA and rheumatoid arthritis. Ann Med. 2014. (PMID 24813459) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md
Perera J, et al. Seropositive and seronegative RA phenotypes, biomarkers and synovium. 2024. (PMID 38727279) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md
de Pablo P, et al. Imaging tests predicting RA in unclassified arthritis. RMD Open. 2022. (PMID 34782180) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md
Mandl P, et al. Imaging for treat to target in RA. Rheumatology. 2019. (PMID 31518423) Adjacent evidence from biomarkers-and-tissue-precision.md, classification-and-diagnosis.md, epidemiology-and-burden.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md, treat-to-target-and-remission.md
He S, et al. Plasma protein biomarkers predating onset and treatment response in RA. 2025. (PMID 40691443) Adjacent evidence from biomarkers-and-tissue-precision.md, genetics-environment-and-mucosal-origins.md, preclinical-autoimmunity-and-prevention.md
Ling SF, et al. Pharmacogenetics of methotrexate response in RA. 2020. (PMID 31849277) Adjacent evidence from biomarkers-and-tissue-precision.md, conventional-dmards.md, genetics-environment-and-mucosal-origins.md, preclinical-autoimmunity-and-prevention.md
Caproli A, et al. Calprotectin as a biomarker in RA. 2023. (PMID 37584369) Adjacent evidence from biomarkers-and-tissue-precision.md, genetics-environment-and-mucosal-origins.md, preclinical-autoimmunity-and-prevention.md
Breedveld FC, et al. PREMIER: adalimumab plus methotrexate versus monotherapies. Arthritis Rheum. 2006;54:26-37. (PMID 16385520) Adjacent evidence from biologic-dmards.md
Klareskog L, et al. Etanercept plus methotrexate versus each alone: TEMPO. Lancet. 2004;363:675-681. (PMID 15001324) Adjacent evidence from biologic-dmards.md
Jones G, et al. Tocilizumab versus methotrexate monotherapy: AMBITION. Ann Rheum Dis. 2010;69:88-96. (PMID 19297346) Adjacent evidence from biologic-dmards.md
Cohen SB, et al. Rituximab after anti-TNF failure: REFLEX. Arthritis Rheum. 2006;54:2793-2806. (PMID 16947627) Adjacent evidence from biologic-dmards.md
Fleischmann R, et al. Abatacept and adalimumab in early RA with poor prognostic factors: AMPLE. Rheumatol Ther. 2019;6:559-571. (PMID 31642045) Adjacent evidence from biologic-dmards.md
Rech J, et al. ARIAA abatacept prevention trial. Lancet. 2024. (PMID 38364841) Adjacent evidence from biologic-dmards.md, clinical-trials-landscape.md, epidemiology-and-burden.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md
Cope AP, et al. APIPPRA abatacept prevention trial. Lancet. 2024. (PMID 38364839) Adjacent evidence from biologic-dmards.md, clinical-trials-landscape.md, epidemiology-and-burden.md, genetics-environment-and-mucosal-origins.md, overview.md, preclinical-autoimmunity-and-prevention.md
Lee YH, et al. Tocilizumab, rituximab, abatacept and tofacitinib after TNF failure: network meta-analysis. Rheumatol Int. 2016. (PMID 26692536) Adjacent evidence from biologic-dmards.md
Sung YK, et al. Comparative biologic efficacy after TNF-inhibitor failure. Int J Clin Pharmacol Ther. 2022. (PMID 34622767) Adjacent evidence from biologic-dmards.md
Evidence-map records are listed in full below and were live-retrieved from PubMed in this build session.

Open questions

  • Are fibroblast and macrophage states causes of persistence or reversible consequences of inflammation? (Schonfeldova 2022, PMID 34559213)
  • Which spatial cell interaction predicts response better than bulk expression?
  • Can residual tissue inflammation identify safe tapering candidates?
  • Why do validated cytokine targets leave a substantial nonresponder fraction across mechanisms? (Humby 2021, PMID 33485455)
  • Can tissue-directed therapies eliminate pathogenic stromal states without disrupting joint homeostasis?

References

  1. Jang S, et al. Rheumatoid Arthritis: Pathogenic Roles of Diverse Immune Cells. Int J Mol Sci. 2022;23:905. PMID 35055087
  2. Schonfeldova B, et al. Synovial single-cell heterogeneity, zonation and interactions: a patchwork of effectors in arthritis. Rheumatology (Oxford). 2022;61:913-925. PMID 34559213
  3. Komatsu N, et al. Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions. Nat Rev Rheumatol. 2022;18:415-429. PMID 35705856
  4. Knab K, et al. Synovial Macrophage and Fibroblast Heterogeneity in Joint Homeostasis and Inflammation. Front Med (Lausanne). 2022;9:862161. PMID 35547214
  5. Kemble S, et al. Critical Role of Synovial Tissue-Resident Macrophage and Fibroblast Subsets in the Persistence of Joint Inflammation. Front Immunol. 2021;12:715894. PMID 34539648
  6. Humby F, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021;397:305-317. PMID 33485455
  7. Lipsky PE, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-602. PMID 11096166
  8. Gabay C, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381:1541-50. PMID 23515142
  9. Pap T, et al. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. 2000;2:361-7. PMID 11094449
  10. Cheng L, et al. New Insights From Single-Cell Sequencing Data: Synovial Fibroblasts and Synovial Macrophages in Rheumatoid Arthritis. Front Immunol. 2021;12:709178. PMID 34349767
  11. Matsuda K, et al. New Insights into the Role of Synovial Fibroblasts Leading to Joint Destruction in Rheumatoid Arthritis. Int J Mol Sci. 2023;24:5173. PMID 36982247
  12. Rivellese F, et al. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med. 2022;28:1256-1268. PMID 35589854
  13. Zhang F, et al. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature. 2023;623:616-624. PMID 37938773
  14. Kurowska-Stolarska M, et al. Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission. Nat Rev Rheumatol. 2022;18:384-397. PMID 35672464
  15. Hu X, et al. Deconvolution of synovial myeloid cell subsets across pathotypes and role of COL3A1+ macrophages in rheumatoid arthritis remission. Front Immunol. 2024;15:1307748. PMID 38601143
  16. Murray-Brown W, et al. Differential expansion of T peripheral helper cells in early rheumatoid arthritis and osteoarthritis synovium. RMD Open. 2022;8:e002563. PMID 36270740
  17. Vickovic S, et al. Three-dimensional spatial transcriptomics uncovers cell type localizations in the human rheumatoid arthritis synovium. Commun Biol. 2022;5:129. PMID 35149753
  18. Tasaki S, et al. Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. Nat Commun. 2018;9:2755. PMID 30013029
  19. Bhamidipati K, et al. Precision medicine in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2022;36:101742. PMID 35248489
  20. Atzeni F, et al. Biomarkers in Rheumatoid Arthritis. Isr Med Assoc J. 2017;19:512-516. PMID 28825772
  21. van Heemst J, et al. HLA and rheumatoid arthritis: how do they connect?. Ann Med. 2014;46:304-10. PMID 24813459
  22. Perera J, et al. Clinical Phenotypes, Serological Biomarkers, and Synovial Features Defining Seropositive and Seronegative Rheumatoid Arthritis: A Literature Review. Cells. 2024;13:743. PMID 38727279
  23. de Pablo P, et al. Systematic review of imaging tests to predict the development of rheumatoid arthritis in people with unclassified arthritis. Semin Arthritis Rheum. 2022;52:151919. PMID 34782180
  24. Mandl P, et al. The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. Rheumatology (Oxford). 2019;58:2091-2098. PMID 31518423
  25. He S, et al. A longitudinal cohort study uncovers plasma protein biomarkers predating clinical onset and treatment response of rheumatoid arthritis. Nat Commun. 2025;16:6692. PMID 40691443
  26. Ling SF, et al. Pharmacogenetics of methotrexate response in rheumatoid arthritis: an update. Pharmacogenomics. 2020;21:3-6. PMID 31849277
  27. Caproli A, et al. Calprotectin as a biomarker in rheumatoid arthritis: the potential predictive value of response to treatment. Bioanalysis. 2023;15:1111-1113. PMID 37584369
  28. Breedveld FC, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37. PMID 16385520
  29. Klareskog L, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675-81. PMID 15001324
  30. Jones G, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88-96. PMID 19297346
  31. Cohen SB, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. PMID 16947627
  32. Fleischmann R, et al. Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). Rheumatol Ther. 2019;6:559-571. PMID 31642045
  33. Rech J, et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024;403:850-859. PMID 38364841
  34. Cope AP, et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet. 2024;403:838-849. PMID 38364839
  35. Lee YH, et al. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis. 2016;19:1103-1111. PMID 26692536
  36. Sung YK, et al. Comparative efficacy and safety of biologic agents in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther. 2022;60:13-23. PMID 34622767